ArticleInvestigative ophthalmology & visual science2026
Directional Analysis of Residual RPE Area Loss in the Natural History of Choroideremia.
Article in Investigative ophthalmology & visual science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To longitudinally evaluate whether residual RPE area loss in choroideremia (CHM) demonstrates directional asymmetry over 12 months. Methods: This study analyzed 106 participants (163 eyes) from the Natural History of the Progression of Choroideremia Study cohort with eligible paired baseline and month 12 fundus autofluorescence imaging. Rigid image registration was performed to align baseline and follow-up images. Residual RPE area reduction was quantified using a progression heatmap and segmented into 12 clock-hour sectors. Directional differences were assessed using generalized estimating equations accounting for within-eye clustering and baseline area. A supplementary analysis evaluated within-eye variance with bootstrap-derived confidence intervals. Results: Across all sectors, the mean RPE area reduction ranged from -0.0236 to -0.0404 mm² equivalents (estimated marginal means). Although minor numerical differences were observed, no statistically significant directional effect was detected after accounting for intraeye correlation. Within-eye variance was low (mean 0.0051; 95% confidence interval, 0.0031-0.0076), indicating limited spatial heterogeneity in progression over 12 months. Conclusions: In this longitudinal analysis of CHM, residual RPE area loss did not demonstrate a consistent directional predilection over 12 months. These findings suggest that short-term structural progression in CHM may occur relatively symmetrically rather than preferentially along specific meridians. A comprehensive assessment of the entire lesion boundary may therefore be more appropriate than direction-specific monitoring in natural history studies and therapeutic trials.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.